AOAC Research Institute grants first certification for cannabis potency testing
by Staff Writers
Rockville MD (TDN) Nov 03, 2022
The AOAC Research Institute granted its first-ever Reviewed and RecognizedSM (R2) certificate to Viridis Laboratories for the LOM 7.1c Cannabinoid Analysis in Flower method using an Ultra-High Pressure Liquid Chromatography (UHPLC) coupled with a Diode Array Detector (DAD), LOM 7.1c Cannabinoid Analysis in Flower by UHPLC-DAD.
"We are pleased to announce that Viridis Laboratories is the first company to complete our rigorous R2 program verifying the performance claims of the method," said Scott Coates, AOAC Research Institute Senior Director. "Viridis has demonstrated a high degree of scientific and analytical excellence."
The method underwent an extensive evaluation process that involved several rounds of reporting and review, along with rigorous testing from an independent third-party laboratory and third-party scientific review panel in order to be the first-ever company to complete the R2 program.
The AOAC Research Institute is a division of AOAC INTERNATIONAL and is an independent third-party organization that sets standards for testing methods for food safety and other products impacting public health, including cannabis. The R2 program is a new AOAC service developed to meet the needs of the analytical science community.
All R2-certified methods are evaluated for accuracy, repeatability, limit of detection, and selectivity. Only methods that meet specified criteria are granted R2 status. Certificates and certification reports are posted for public access on the AOAC website.
AOAC also operates the internationally renowned Cannabis Analytical Science Program (CASP). The CASP program developed the Standard Methods Performance Requirements (SMPR) which prescribes the acceptance criteria for evaluating cannabis potency methods.
Neuraxpharm launches European campaign to increase awareness of medical cannabis
Barcelona, Spain (TDN) Oct 31, 2022
Neuraxpharm, a leading European specialty pharmaceutical company, has announced its "Change for Health" campaign that aims to increase the acceptance of medical cannabis and provide better information to patients, physicians and pharmacies. Based on the concept "If we turn our back on medical cannabis, we turn our back on millions of patients" Neuraxpharm is fostering a change for health across society on medical cannabis as a treatment to help improve the quality of life of hundreds of thousands ... read more
|The content herein, unless otherwise known to be public domain, are Copyright 2020-2022 - THE DAILY NETWORK LLC. Additional copyrights may apply in whole or part to other bona fide parties. All websites are published in United States of America and are solely subject to US law and governed by Fair Use principals for news reporting and research purposes. No Content or Advertising herein implies endorsement, agreement or approval of any opinions, statements or information provided by THE DAILY NETWORK LLC on any Web page published or hosted by THE DAILY NETWORK LLC. Questions? Email Editor@IndicaDaily.com Privacy Statement|